Systemic aspirin and systemic vitamin E in senile cataracts: cataract V.
We undertook a prospective study in senile cataract patients using systemic aspirin and systemic vitamin E. Vitamin E treated eyes did show less progression of PSC opacities extent and less new nuclear opacities during the follow-up, but overall vitamin E treated eyes did no better than the control group eyes. More eyes in systemic aspirin treated group maintained the initial vision and loss of vision in the aspirin group was also less marked. Aspirin also caused a significant less mean increase in cortical opacity extent, nuclear/opacity and density and PSC opacity extent and density as well as in ophthalmoscopically graded opacity extent and density. We suggest that aspirin is a potential drug which should be further evaluated in large double blind photodocumentated studies. The present data does not justify the recommendation that aspirin be prescribed for slowing down cataract progression. This must await large studies and confirmation.
Sharma
Y R
YR
Vajpayee
R B
RB
Bhatnagar
R
R
Mohan
M
M
Azad
R V
RV
Kumar
M
M
Nath
R
R
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000375:Aging; D001241:Aspirin / Q000627:therapeutic use*; D002386:Cataract / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014810:Vitamin E / Q000627:therapeutic use*
D014810:Vitamin E; D001241:Aspirin